
ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport academic.oup.com/cardiovascres/…
Great to see this out. Wonderful collaboration with @PeterVangheluwe and team!
English
Nick Morrell
811 posts

@NickMorrell15
Clinician scientist, lung doc, co-Founder of Morphogen-IX and Interact Bio Ltd, developing better treatments for pulmonary arterial hypertension.


We are delighted to announce that today we have become the Victor Phillip Dahdaleh Heart & Lung Research Institute to honour a very generous philanthropic donation from @victordahdaleh @Cambridge_Uni @RoyalPapworth @CUHPartners






Inspiring talk from @mark_toshner showing a genuine bench to bedside approach to help transform the research approach in a rare disease - including remote/digital monitoring to help patient involvement. Brilliant. #BTSWinter2022


















